BOSTON, Nov. 27, 2023 -- Regor Therapeutics (“Regor”), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that a poster presentation featuring First-in-human Phase 1A study of RGT-419B, will be reported at the San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023, in San Antonio, Texas.

Details of the SABCS 2023 poster presentations are:

Title:	First-in-human Phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with HR+/HER2- ABC who progressed on prior CDK4/6 inhibitors
Poster ID:	PO3-18-06
Session Title:	Poster Session 3
Date:	Thursday December 7, 2023
Time:	12:00 p.m. to 2:00 p.m. CST

A copy of the poster will be made available on Regor’s website under the Sciences & Technology section when it is presented at the symposium. Abstracts for the posters can be found on the SABCS website Full Program (sabcs.org).

About Regor Therapeutics

Regor Therapeutics is a global biotech company founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. By leveraging its industry-leading core strength in rCARD^TM(Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor’s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.

Regor’s in-house pipeline encompasses leading assets in metabolism, oncology and auto-immunity, with 2 leading assets: 1) RGT-075, an orally bioavailable small molecule GLP1R full agonist with best-in-class potential for obesity & beyond; and 2) RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/Her2- breast cancer patients.

With a strong focus on excellence in pharmaceutical research and global competitiveness, Regor aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.

IR Contact:

  Investor Relations and Communications

  Email: ir@regor.com